Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
:CSTL
CSTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.45 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)413.86K
Market Cap
$485.05M
Enterprise Value$480.98M
Total Cash (Recent Filing)$275.15M
Total Debt (Recent Filing)$25.84M
Price to Earnings (P/E)30.6
Beta0.90
Next Earnings
Aug 04, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding28,872,314
10 Day Avg. Volume370,171
30 Day Avg. Volume413,862
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio13.07
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.38
Enterprise Value/Gross Profit1.61
Enterprise Value/Ebitda4.38
Forecast
1Y Price Target
$35.83Price Target Upside113.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences Holds Annual Stockholders Meeting
Bulls Say, Bears Say
Bulls Say
Market PositionCastle Biosciences is seen as a leading skin cancer diagnostics company with a growing position in gastrointestinal cancer diagnostics.
Strategic PartnershipsCastle Biosciences enters a collaboration and license agreement with SciBase Holding AB to develop a diagnostic test for atopic dermatitis.
Bears Say
Growth Strategy RisksThere is material risk to the company executing on its growth strategy.
Reimbursement UncertaintyThere is uncertainty regarding the SCC reimbursement status, which could impact CSTL's profitability.
Ownership Overview
2.68% Insiders
27.23% Mutual Funds
0.18% Other Institutional Investors
55.51% Public Companies and
Individual Investors
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $15.45 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $485.05M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Aug 04, 2025 which is in 9 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on May 05, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.069 by -$0.831.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.53.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 28,872,314 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.069. Following the earnings report the stock price went down -11.36%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.83 (113.27% Upside)
$35.83 (113.27% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 34.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.22%
12-Months-Change
Fundamentals
Return on Equity
-1.20%
Trailing 12-Months
Asset Growth
9.42%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strategic acquisitions, particularly the acquisition of Previse and the strong performance of TissueCypher. However, challenges were noted in gross margin decline, discontinuation of IDgenetix, and reimbursement issues for DecisionDx-SCC. Despite these challenges, the positive developments appear to outweigh the negatives.Read More>CSTL Stock 12 Month Forecast
Average Price Target
$35.83
▲(113.27%Upside)